NASDAQ:IMTX - Immatics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.80
  • Forecasted Upside: 66.51 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$10.69
▲ +0.19 (1.81%)
1 month | 3 months | 12 months
Get New Immatics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$17.80
▲ +66.51% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Immatics in the last 3 months. The average price target is $17.80, with a high forecast of $28.00 and a low forecast of $13.00. The average price target represents a 66.51% upside from the last price of $10.69.
Buy
The current consensus among 5 contributing investment analysts is to buy stock in Immatics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2020

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2020Bank of AmericaInitiated CoverageBuy$13.00Low
i
9/21/2020The Goldman Sachs GroupInitiated CoverageBuy$17.00High
i
8/18/2020Chardan CapitalReiterated RatingBuy$28.00Medium
i
7/27/2020SVB LeerinkInitiated CoverageOutperform$17.00High
i
Rating by J. Chang at SVB Leerink LLC
7/24/2020Jefferies Financial GroupInitiated CoverageBuy$14.00High
i
(Data available from 11/23/2015 forward)
Immatics logo
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors; and IMA204, an anti-tumor therapy that targets the malignant tumor cell. Its TCR Bispecifics product candidates include IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid and hematological malignancies. The company also develops IMA101, a multi-target precision immunotherapy; and IMA301, an off-the-shelf ACT. It has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in Tübingen, Germany.
Read More

Today's Range

Now: $10.69
$10.55
$11.06

50 Day Range

MA: $10.80
$9.90
$12.05

52 Week Range

Now: $10.69
$8.66
$17.48

Volume

121,440 shs

Average Volume

190,671 shs

Market Capitalization

$192.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A